BerGenBio ASA (OSL:BGBIO)
1.832
-0.098 (-5.08%)
May 30, 2025, 4:25 PM CET
BerGenBio ASA Company Description
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and immune-evasive in Norway.
The company’s lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and BGBIL025, a JAK2 inhibitor, which is in preclinical stage for treatment of the bone marrow disorder myelofibrosis.
BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway.
BerGenBio ASA

Country | Norway |
Founded | 2007 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 13 |
CEO | Olav Hellebo |
Contact Details
Address: Nygardsgaten 114 Bergen, 5008 Norway | |
Phone | 47 55 96 11 59 |
Website | bergenbio.com |
Stock Details
Ticker Symbol | BGBIO |
Exchange | Oslo Børs |
Fiscal Year | January - December |
Reporting Currency | NOK |
ISIN Number | NO0010650013 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Olav Hellebo BBA, MBA | Chief Executive Officer |
Rune Skeie | Chief Financial Officer |
Cristina Oliva M.D. | Chief Medical Officer |
Graham Morell | Head of IR |
Gayle M. Mills M.B.A | Chief Business Officer |
Dr. Akil Jackson | Medical Director |